Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Bevacizumab, and Erlotinib in Advanced Pancreatic Cancer
NCT00366457Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2006
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by Massachusetts General Hospital. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00366457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366457.